Displaying 361 - 372 of 465
Viral Hepatitis
Plenary – ‘Short Duration DAAs: Fuelling the Journey to HCV Elimination’

Plenary – ‘Short Duration DAAs: Fuelling the Journey to HCV Elimination’

Webcasts
View
Viral Hepatitis
Structured faculty discussion – ‘How Can We Increase the Momentum Towards an HCV-free World?’

Structured faculty discussion – ‘How Can We Increase the Momentum Towards an HCV-free World?’

Webcasts
View
Viral Hepatitis
Audience Q&A and Close

Audience Q&A and Close

Webcasts
View
Viral Hepatitis
Case studies – ‘Best Practices for Optimizing HCV Care’

Case studies – ‘Best Practices for Optimizing HCV Care’

Webcasts
View
Viral Hepatitis
Case studies – ‘Best Practices for Optimizing HCV Care’

Case studies – ‘Best Practices for Optimizing HCV Care’

Webcasts
View
Metabolism, Alcohol & Toxicity
Why we need to talk about NASH

Why we need to talk about NASH

Webcasts
View
Metabolism, Alcohol & Toxicity
Hepatic consequences of metabolic dysregulation: NAFLD and NASH

Hepatic consequences of metabolic dysregulation: NAFLD and NASH

Webcasts
View
Metabolism, Alcohol & Toxicity
Looking ahead: how to identify high-risk patients

Looking ahead: how to identify high-risk patients

Webcasts
View
Metabolism, Alcohol & Toxicity
Navigating the NASH healthcare system: global insights and challenges (panel discussion and Q&A)

Navigating the NASH healthcare system: global insights and challenges (panel discussion and Q&A)

Webcasts
View
Metabolism, Alcohol & Toxicity
The NASH treatment pipeline: focus on anti-metabolic approaches

The NASH treatment pipeline: focus on anti-metabolic approaches

Webcasts
View
Metabolism, Alcohol & Toxicity
Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases

Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases

Webcasts
View
Metabolism, Alcohol & Toxicity
Q&A

Q&A

Webcasts
View